Top

BMC Cancer

Published in:

Open Access 01-12-2020 | osteosarcoma | Research article

Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients

Authors: Chuan Hu, Chuan Liu, Shaoqi Tian, Yuanhe Wang, Rui Shen, Huili Rao, Jianyi Li, Xu Yang, Bo Chen, Lin Ye

Published in: BMC Cancer | Issue 1/2020

Abstract

Background

Tumor microenvironment (TME) plays an important role in malignant tumors. Our study aimed to investigate the effect of the TME and related genes in osteosarcoma patients.

Methods

Gene expression profiles and clinical data of osteosarcoma patients were downloaded from the TARGET dataset. ESTIMATE algorithm was used to quantify the immune score. Then, the association between immune score and prognosis was studied. Afterward, a differential analysis was performed based on the high- and low-immune scores to determine TME-related genes. Additionally, Cox analyses were performed to construct two prognostic signatures for overall survival (OS) and disease-free survival (DFS), respectively. Two datasets obtained from the GEO database were used to validate signatures.

Results

Eighty-five patients were included in our research. The survival analysis indicated that patients with higher immune score have a favorable OS and DFS. Moreover, 769 genes were determined as TME-related genes. The unsupervised clustering analysis revealed two clusters were significantly related to immune score and T cells CD4 memory fraction. In addition, two signatures were generated based on three and two TME-related genes, respectively. Both two signatures can significantly divide patients into low- and high-risk groups and were validated in two GEO datasets. Afterward, the risk score and metastatic status were identified as independent prognostic factors for both OS and DFS and two nomograms were generated. The C-indexes of OS nomogram and DFS nomogram were 0.791 and 0.711, respectively.

Conclusion

TME was associated with the prognosis of osteosarcoma patients. Prognostic models based on TME-related genes can effectively predict OS and DFS of osteosarcoma patients.

Available only for authorised users

Jaffe N, Bruland OS, Bielack S. Pediatric and adolescent osteosarcoma, vol. 152. New York: Springer Science & Business Media; 2010.

Vander RG. Osteosarcoma and its variants. Orthopedic Clin North Am. 1996;27(3):575–81.CrossRef

Biermann JS, Adkins D, Benjamin R, Brigman B, Chow W, Conrad EU 3rd, Frassica D, Frassica FJ, George S, Healey JH, et al. Bone cancer. J Natl Compr Cancer Netw. 2007;5(4):420–37.CrossRef

Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP, Rutland CS. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Vet Scand. 2017;59(1):71.PubMedPubMedCentralCrossRef

Chen X, Cates JM, Du Y-C, Jain A, Jung SY, Li X-N, Hicks JM, Man TK. Mislocalized cytoplasmic p27 activates PAK1-mediated metastasis and is a prognostic factor in osteosarcoma. Mol Oncol. 2020;14(4):846–64.PubMedPubMedCentralCrossRef

Huang X, Yang W, Zhang Z, Shao Z. Dysregulated circRNAs serve as prognostic and diagnostic markers in osteosarcoma by sponging microRNA to regulate the downstream signaling pathway. J Cell Biochem. 2019;121(2):1834–41.

Liu M, Yang P, Mao G, Deng J, Peng G, Ning X, Yang H, Sun H. Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: a systematic review and meta-analysis. Int J Surg. 2019;72:206–13.PubMedCrossRef

Xu K, Xiong W, Zhao S, Wang B. MicroRNA-106b serves as a prognostic biomarker and is associated with cell proliferation, migration, and invasion in osteosarcoma. Oncol Lett. 2019;18(3):3342–8.PubMedPubMedCentral

Zheng W, Huang Y, Chen H, Wang N, Xiao W, Liang Y, Jiang X, Su W, Wen S. Nomogram application to predict overall and cancer-specific survival in osteosarcoma. Cancer Manag Res. 2018;10:5439.PubMedPubMedCentralCrossRef

10.

Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med. 2013;91(4):431–7.PubMedCrossRef

11.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50.PubMedPubMedCentral

12.

Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.PubMedCrossRef

13.

Yang S, Liu T, Nan H, Wang Y, Chen H, Zhang X, Zhang Y, Shen B, Qian P, Xu S, et al. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma. J Cell Physiol. 2020;235(2):1025–35.PubMedCrossRef

14.

Deng Z, Wang J, Xu B, Jin Z, Wu G, Zeng J, Peng M, Guo Y, Wen Z. Mining TCGA database for tumor microenvironment-related genes of prognostic value in hepatocellular carcinoma. Biomed Res Int. 2019;2019:2408348.

15.

Zhao K, Yang H, Kang H, Wu A. Identification of key genes in thyroid Cancer microenvironment. Med Sci Monit. 2019;25:9602.PubMedPubMedCentralCrossRef

16.

Xu W-H, Xu Y, Wang J, Wan F-N, Wang H-K, Cao D-L, Shi G-H, Qu Y-Y, Zhang H-L, Ye D-W. Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging (Albany NY). 2019;11(17):6999.CrossRef

17.

Chen B, Chen W, Jin J, Wang X, Cao Y, He Y. Data Mining of Prognostic Microenvironment-Related Genes in clear cell renal cell carcinoma: a study with TCGA database. Dis Markers. 2019;2019:8901649.

18.

Li X, Gao Y, Xu Z, Zhang Z, Zheng Y, Qi F. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods. Cancer Med. 2019;9(3):1161–72.

19.

Pan X-B, Lu Y, Huang J-L, Long Y, Yao D-S. Prognostic genes in the tumor microenvironment in cervical squamous cell carcinoma. Aging (Albany NY). 2019;11(22):10154.CrossRef

20.

Wang H, Wu X, Chen Y. Stromal-immune score-based gene signature: a prognosis stratification tool in gastric Cancer. Front Oncol. 2019;9:1212.PubMedPubMedCentralCrossRef

21.

Huang S, Zhang B, Fan W, Zhao Q, Yang L, Xin W, Fu D. Identification of prognostic genes in the acute myeloid leukemia microenvironment. Aging (Albany NY). 2019;11(22):10557.CrossRef

22.

Yan H, Qu J, Cao W, Liu Y, Zheng G, Zhang E, Cai Z. Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis. Cancer Immunol Immunother. 2019;68(12):1971–8.PubMedCrossRef

23.

Luo Y, Zeng G, Wu S. Identification of microenvironment-related prognostic genes in bladder Cancer based on gene expression profile. Front Genet. 2019;10:1187.PubMedPubMedCentralCrossRef

24.

Buddingh EP, Kuijjer ML, Duim RA, Bürger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011;17(8):2110–9.PubMedCrossRef

25.

Kelly AD, Haibe-Kains B, Janeway KA, Hill KE, Howe E, Goldsmith J, Kurek K, Perez-Atayde AR, Francoeur N, Fan JB, et al. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome medicine. 2013;5(1):2.PubMedPubMedCentralCrossRef

26.

Smyth GK. Limma: linear models for microarray data. In: Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. p. 397–420.

27.

Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.PubMedPubMedCentralCrossRef

28.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453.PubMedPubMedCentralCrossRef

29.

Wilkerson M, Hayes D. ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics (Oxford, England). 2010;26:1572–3.CrossRef

30.

Hintze JL, Nelson RD. Violin plots: a box plot-density trace synergism. Am Stat. 1998;52(2):181–4.

31.

Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.PubMedCrossRef

32.

Wang Z, Zhu J, Liu Y, Liu C, Wang W, Chen F, Ma L. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. J Transl Med. 2020;18(1):67.PubMedPubMedCentralCrossRef

33.

Zhang C, Zheng J-H, Lin Z-H, Lv H-Y, Ye Z-M, Chen Y-P, Zhang X-Y. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging (Albany NY). 2020;12(4):3486.CrossRef

34.

Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2003;21(10):2011–8.PubMedCrossRef

35.

Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125(1):229–34.PubMedPubMedCentralCrossRef

36.

Hu B, Yang X-B, Sang X-T. Development of an immune-related prognostic index associated with hepatocellular carcinoma. Aging (Albany NY). 2020;12(6):5010.CrossRef

37.

New M, Van Acker T, Sakamaki J-I, Jiang M, Saunders RE, Long J, Wang VM-Y, Behrens A, Cerveira J, Sudhakar P. MDH1 and MPP7 regulate autophagy in pancreatic ductal adenocarcinoma. Cancer Res. 2019;79(8):1884–98.PubMedPubMedCentralCrossRef

38.

Yang C, Zhou Q, Li M, Tong X, Sun J, Qing Y, Sun L, Yang X, Hu X, Jiang J. Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines. Sci Rep. 2016;6(1):1–11.CrossRef

39.

Liu X, Cao Y, Li R, Gu Y, Chen Y, Qi Y, Lv K, Wang J, Yu K, Lin C. Poor clinical outcomes of intratumoral dendritic cell–specific intercellular adhesion molecule 3–grabbing non-integrin–positive macrophages associated with immune evasion in gastric cancer. Eur J Cancer. 2020;128:27–37.PubMedCrossRef

40.

Ahmadipour Y, Gembruch O, Pierscianek D, Sure U, Jabbarli R. Does the expression of glial fibrillary acid protein (GFAP) stain in glioblastoma tissue have a prognostic impact on survival? Neurochirurgie. 2020;66(3):150–4.

41.

Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, Berger P, Desborough V, Smith T, Campbell J. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58(2–3):234–9.PubMedCrossRef

42.

Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S, Wu A. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86(24):2226–34.CrossRefPubMed

43.

Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S, Murray GI. Cytochrome P450 profile of colorectal Cancer: identification of markers of prognosis. Clin Cancer Res. 2005;11(10):3758–65.PubMedCrossRef

44.

Yong GK, Mi JK, Lim JS, Lee MS, Kim JS, Yoo YD. ICAM-3-induced cancer cell proliferation through the PI3K/Akt pathway. Cancer Lett. 2006;239(1):0–110.

45.

Park JK, Park SH, So K, Bae IH, Um HD. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int J Oncol. 2010;36(1):181–92.PubMed

Title: Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients
Authors: Chuan Hu
Chuan Liu
Shaoqi Tian
Yuanhe Wang
Rui Shen
Huili Rao
Jianyi Li
Xu Yang
Bo Chen
Lin Ye
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: osteosarcoma
Osteosarcoma
Published in: BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-07216-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study

Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis

Effects of reduced platelet count on the prognosis for patients with non-small cell lung cancer treated with EGFR-TKI: a retrospective study

Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines

Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report

Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer